Private Label CBD Gummies Market : Global Industry Analysis 2016 - 2025 and Opportunity Assessment 2026 - 2036

Private Label CBD Gummies Market Size, Market Forecast and Outlook By FMI

The private label CBD gummies market is expected to grow from USD 598.9 million in 2025 to USD 1,382.2 million by 2036 at 7.9% CAGR. Growth is supported by lower brand launch cost and demand for ready gummy formats, while white label gummies are expected to hold 46.2% share in 2026 and broad-spectrum CBD gummies are forecast to lead spectrum demand with 42.8% share as brands prioritize faster market entry and cleaner label control.

Summary of Private Label CBD Gummies Market

• Demand and Growth Drivers
  • Brands choose private label gummies because they can enter the CBD edible space faster than building a production line.
  • White label formats reduce early product risk because formulas and packaging routes are already defined.
  • Retailers prefer suppliers that can support clear serving size and clean product documents.
• Product and Segment View
  • Broad-spectrum CBD gummies appeal to brands that want THC-free positioning and clearer product messaging.
  • Custom formulation supports brands that want sleep or daily wellness gummies under their own label.
  • Brand websites help new CBD gummy brands explain dose and testing before buyers place repeat orders.
• Geography and Competitive Outlook
  • The United States has broad private label CBD gummy activity because DTC brands and contract manufacturers are well developed.
  • Canada and Australia depend more on regulated access and careful product review.
  • European markets need more complete compliance files because CBD food and edible claims face closer checks.
• Analyst Opinion
  • Nandini Roy Choudhury, Principal Consultant for Food and Beverage at FMI, notes, “Private label CBD gummies offer a launch route for wellness brands. The next test is not flavor alone. Brand owners will need partners that can manage testing, warning labels and retail-ready documentation without making CBD claims too broad.”
• Private Label CBD Gummies Market Value Analysis
  • The private label CBD gummies market is moving from simple outsourced production into a clearer brand-building route.
  • Market value is driven by smaller wellness brands that want gummies without owning extraction or confectionery assets.
  • White label formats reduce launch time because the supplier already has gummy base work and packaging options in place.
  • Demand is supported by online selling, batch documentation and retailer requests for cleaner CBD product files.

Private label CBD gummies are becoming a practical route for wellness brands that want to enter CBD edibles without building their own gummy plant. Contract partners handle formulation and testing. Packaging support completes the launch route. This allows brand owners to focus on channel building and customer education. Suppliers serving CBD gummies demand need strong batch files because edible CBD rules are becoming more closely reviewed.

Private Label CBD Gummies Market Definition

Private label CBD gummies market covers gummy products containing cannabidiol that are manufactured by a third-party supplier and sold under a separate brand owner’s label. Scope includes white label gummies and custom CBD gummy formulations. Contract-manufactured gummies, co-packed gummies and bulk gummies are included when products are supplied for resale.

Private Label CBD Gummies Market Inclusions

Market scope covers private label CBD gummy products categorized by service model, including white label gummies, custom formulation, contract manufacturing, co-packing, and bulk gummies. CBD spectrum coverage includes broad-spectrum CBD gummies, full-spectrum CBD gummies, CBD isolate gummies, minor cannabinoid blends, and THC-free gummies. Dosage coverage includes low dose, mid dose, high dose, microdose, and split dose gummies. Sales channel coverage includes brand websites, specialist retail, pharmacy-style retail, licensed cannabis retail, and marketplace sellers. Buyer coverage includes startup brands, wellness retailers, cannabis retailers, practitioner brands, and digital wellness brands. Revenue scope covers 2026 to 2036. The key stakeholders include private label CBD manufacturers, hemp extract suppliers, gummy formulators, testing labs, packaging suppliers, brand owners, online retailers, licensed cannabis retailers, compliance consultants, and regulatory bodies.

Private Label CBD Gummies Market Exclusions

Scope excludes branded CBD gummies sold only under the manufacturer’s own label. CBD oils, tinctures and capsules are outside the private label gummy boundary. Topicals, vapes and beverages are excluded. Smokable hemp products are excluded. THC-intoxicating gummies are excluded unless the product is sold through a legal regulated route and CBD is part of the named formulation. Non-CBD functional gummies are excluded unless they are sold in a defined private label CBD gummy line. Saudi Arabia and GCC countries are treated only as exclusion or compliance reference markets.

Private Label CBD Gummies Market Research Methodology

• Primary Research: Future Market Insights analysts reviewed product portfolios, private label cannabidiol gummy pages, certificate of analysis access, packaging options, minimum order signals, serving-size information, and compliance wording from active companies. Company review included CBD Nationwide, Extract Labs, cbdMD, Inc., Charlotte’s Web Holdings, Inc., CV Sciences, Inc., Medterra CBD LLC, British Cannabis, Cannaray Limited, MediPharm Labs Corp., and Little Green Pharma Ltd.
• Desk Research: Public information from the Food and Drug Administration, Food Standards Agency, Health Canada, USA Census Bureau, Statistics Canada, Office for National Statistics, Federal Ministry of Health Germany, Agence nationale de sécurité sanitaire de l’alimentation, de l’environnement et du travail, Therapeutic Goods Administration, and Government of the Netherlands was reviewed.
• Market Sizing and Forecasting: Estimated using a bottom-up product-boundary approach. Eligible private label gummy revenue, supplier service coverage, retail pricing, product positioning, and country-level adoption were used to construct the 2026 market estimate.
• Data Validation: Forecast checks compared private label supplier coverage, CBD gummy availability, official safety guidance, company product launches, batch testing access, and country-level retail rules. Products without private label, white label, contract manufacturing, or co-packed gummy positioning were excluded from revenue scope.

Why is the Private Label CBD Gummies Market Growing?

• Brand owners want faster entry into CBD edibles without building their own gummy production line.
• Private label suppliers reduce early launch risk by offering ready formulas and packaging routes.
• Retailers look for products backed by batch testing and clear serving size before listing CBD gummies.
• Online brands use private label gummies to test demand before investing in deeper product development.

Private label CBD gummies are expanding because brand owners want a lower-risk route into functional edibles. CBD Nationwide describes private label and contract manufacturing options for brands that want CBD products without owning production assets. This shows how supplier services support faster entry into edible CBD formats. Brand owners using gummy supplements experience can apply familiar daily-use formats while keeping CBD-specific warnings clear.

Market Segmentation Analysis

• In 2026, white label gummies are projected to hold 46.2% share because the format gives new brands a faster launch route and lowers formulation work.
• Broad-spectrum CBD gummies use THC-free positioning to make retailer review easier, with the format forecast to account for 42.8% share in 2026.
• Mid dose gummies are forecast to secure 44.5% dosage share in 2026. The serving level is easier to explain across daily wellness products.
• Brand websites can explain batch reports before first purchase. The channel is forecast to represent 39.6% sales channel share in 2026.
• In 2026, startup wellness brands are estimated to hold 33.8% buyer share because private label supply gives them a lower-cost route into CBD gummies.

The market is divided into five primary segment groups based on service model and CBD spectrum. Dosage strength, sales channel and buyer type complete the structure. Service model covers white label gummies and custom formulation. Contract manufacturing, co-packing and bulk gummies complete the service model scope. CBD spectrum covers broad-spectrum CBD gummies and full-spectrum CBD gummies. CBD isolate gummies and minor cannabinoid blends are included in the spectrum scope. THC-free gummies complete the group. Dosage strength covers low dose and mid dose gummies. High dose, microdose and split dose gummies complete the dose scope. Sales channel covers brand websites and specialist retail. Pharmacy-style retail, licensed cannabis retail and marketplace sellers complete the channel scope. Buyer type covers startup brands and wellness retailers. Cannabis retailers, practitioner brands and digital wellness brands complete the buyer scope.

Insights into Private Label CBD Gummies Market by Service Model

• White label gummies are expected to hold 46.2% share in 2026. The format attracts new brands because the supplier already controls the base formula.
• Custom formulation is expected to serve brands that want sleep or daily wellness gummies with a distinct label story.

Insights into Private Label CBD Gummies Market by CBD Spectrum

• Broad-spectrum CBD gummies are forecast to account for 42.8% share in 2026 with THC-free positioning making the format easier for retailers to review.
• Full-spectrum gummies are expected to serve experienced buyers in 2026. Brands need clear THC wording and stronger batch files before wider retail entry.

Insights into Private Label CBD Gummies Market by Dosage Strength

• Mid dose gummies are expected to secure 44.5% dosage share in 2026 as the serving level fits routine wellness use because it is easier to explain.
• Low dose gummies are expected to work well for first-time brands in 2026. Cautious buyers often want a simple entry format.

Insights into Private Label CBD Gummies Market by Sales Channel

• Brand websites are forecast to represent 39.6% sales channel share in 2026. Product pages give new brands space to explain testing and serving size.
• Specialist retail is expected to expand carefully in 2026. Retailers often review CBD labels before adding private label gummies.

Insights into Private Label CBD Gummies Market by Buyer Type

• Startup wellness brands are expected to hold 33.8% buyer share in 2026. Private label supplies help them test demand before deeper investment.
• Retailer-owned brands are expected to build more interest in 2026. Stores can use private label gummies to improve margin control and repeat purchase.

Private Label CBD Gummies Market Drivers, Restraints, and Opportunities

• Driver: Faster brand launch is turning private label CBD gummies into a practical route for wellness startups.
• Restraint: Claim review risk can limit broad wellness wording across private label CBD gummy products.
• Opportunity: Compliance-ready private label services can create stronger positions for suppliers with testing and packaging support.

Private label CBD gummy demand is moving toward suppliers that can handle label checks and batch documentation. cbdMD launched Max Chill Dragon Fruit Delta 9 Gummies in May 2024. Each gummy contains 10.0 mg Delta 9 THC and 10.0 mg CBD with a 1:1 CBD-to-THC ratio. The launch shows how exact cannabinoid amounts make edible positioning easier to explain. This makes dose control more important for private label suppliers that want to serve brand owners across online and specialist retail channels.

Raw Material Price and Formulation Cost Analysis

Private label CBD gummy cost is influenced by hemp extract type and gummy base selection. Testing and packaging add another cost layer. Broad-spectrum CBD can cost more because THC removal and verification need added process control. European Food Safety Authority set a provisional safe intake level for CBD of 0.0275 mg per kilogram of body weight per day in February 2026. Lower-dose planning can reduce product review pressure in safety-sensitive markets. Private label partners working with CBD product packaging needs can reduce relabeling risk when brands move across retail channels.

Consumer Segmentation and Purchase Behavior Analysis

Private label CBD gummy buyers include startup brands and small retailers. Wellness platforms and practitioner-backed brands complete the buyer group. These buyers often care less about owning production and more about a clean product file. Extract Labs states that private label clients can choose cannabinoids and flavors. It also offers added ingredients and packaging options for client brands. Buyers comparing nutraceutical gummies with private label CBD gummies need stronger cannabinoid testing and clearer product warnings. Brands that explain dose in simple language can reduce first-purchase doubt.

Competitive Landscape and Strategic Positioning

• Private label CBD gummy suppliers hold an advantage when they combine formulation support and batch documentation.
• Brand owners prefer suppliers that can explain CBD spectrum type and serving size in clear language.
• Retailer-owned brands need packaging partners that can manage warning language and product presentation.
• Entry barriers include testing cost and claim review. Label errors can delay launch even when the gummy formula is ready.

Private label CBD gummy market competition is based on supplier reliability and compliance support. Brand owners buy a gummy base plus product files, lab reports and packaging guidance. Suppliers with stronger formulation control can help brands reduce launch delays. Partners with clear testing systems can also make retailer review easier.

Product control is now a practical advantage for suppliers serving private label customers. A brand owner may want a sleep gummy or a daily wellness gummy with the same label system. Suppliers with stronger documentation can help brands avoid delays when labels or ingredients change. Brands entering from CBD snacks may understand edible selling, but CBD gummies need stricter dose and warning language. Packaging and batch access become more important when products move from online channels into stores.

Smaller private label brands can build trust through clear serving sizes and simple product pages. Larger suppliers can win by offering gummy production, testing support and packaging help in one place. Retailers will keep asking for cleaner shelf files as CBD edibles face closer review. Suppliers working with CBD product packaging share analysis priorities can improve label readability and reduce product review friction. Gummy texture work also matters because jellies and gummies experience can help suppliers improve chew and shelf stability.

Key Companies in Private Label CBD Gummies Market

• Private Label Manufacturers: CBD Nationwide and Extract Labs support private label CBD gummy production with formulation and packaging support.
• Brand Owners with Gummy Depth: cbdMD and Charlotte’s Web Holdings, Inc. support market visibility through consumer-facing gummy portfolios.
• Testing-Led Channel Builders: CV Sciences, Inc. and Medterra CBD LLC use product education and lab access to support consumer trust.
• Licensed Cannabis Partners: MediPharm Labs Corp. and Little Green Pharma Ltd. support regulated cannabinoid access in Canada and Australia.
• European Specialists: British Cannabis, Cannaray Limited, and Nordic Oil GmbH support specialist CBD retail in European countries.

Company Benchmarking Table

Company	Private Label Fit	Gummy Formulation Control	Compliance File Strength
CBD Nationwide	High	High	Medium
Extract Labs	High	Medium	Medium
cbdMD, Inc.	Medium	Medium	High
Charlotte’s Web Holdings, Inc.	Medium	High	High
CV Sciences, Inc.	Medium	Medium	High
Medterra CBD LLC	Medium	Medium	High
British Cannabis	Medium	Medium	Medium

Source: Future Market Insights, 2026.

Recent Industry Developments

• In September 2025, CBD Nationwide outlined private label cannabis and hemp scaling guidance for brands. The company linked scaling needs with production control, quality systems, and stronger private label operations.
• In August 2025, Charlotte’s Web Holdings, Inc. reported that in-house gummy production expanded in the second quarter of 2025. The company said Brightside was fully internalized.
• In January 2025, DoorDash added hemp-derived THC and CBD products to on-demand delivery in select USA states. The channel move shows why age checks and product documentation are now more important for CBD gummy sellers.

Key Players in the Private Label CBD Gummies Market

• CBD Nationwide
• Extract Labs
• cbdMD, Inc.
• Charlotte’s Web Holdings, Inc.
• CV Sciences, Inc.
• Medterra CBD LLC
• British Cannabis
• Cannaray Limited
• MediPharm Labs Corp.
• Little Green Pharma Ltd.

Analysis of Private Label CBD Gummies Market by Key Countries

Country	CAGR
United States	8.5%
Canada	8.1%
United Kingdom	7.8%
Germany	7.5%
Australia	7.3%
Netherlands	6.9%
France	6.4%

Source: Future Market Insights, 2026.

Private Label CBD Gummies Market CAGR Analysis by Country

• The United States is expected to record 8.5% CAGR by 2036, driven by private label supplier depth and online CBD brand formation.
• Canada’s 8.1% CAGR reflects regulated edible access and stronger control over cannabinoid product packaging.
• The United Kingdom is forecast to advance at 7.8% CAGR through 2036, with CBD product-list discipline guiding brand entry.
• Germany is expected to rise at 7.5% CAGR from 2026 to 2036, backed by wider cannabinoid awareness and strict retail documentation needs.
• Australia is likely to record 7.3% CAGR during the forecast period, helped by medical cannabis familiarity and pharmacist-linked CBD review.
• The Netherlands is forecast to expand at 6.9% CAGR during the forecast period, with controlled cannabis supply trials improving product-quality discussion.
• France is expected to move at 6.4% CAGR through 2036, with demand moving carefully due to CBD safety review.

Demand Outlook for Private Label CBD Gummies Market in the United States

Large private label supplier base, 2026 to 2036

Country Market Snapshot Table

Parameter	Value
Market Size in 2025 (Value)	USD 286.4 million
Market Forecast in 2036 (Value)	USD 700.4 million
CAGR (2026-2036)	8.5%
Years Considered	2021-2036
Base Year	2025
Forecast Period	2026-2036
Units Considered	Value (USD million)
Leading Sub-Region	West Coast and Colorado manufacturing corridor

United States Private Label CBD Gummies Market Outlook

USA private label CBD gummies demand comes from small wellness brands that want outsourced edible production. Contract suppliers help these brands avoid the cost of building gummy lines.

Brand websites and subscriptions make product education easier. Private label partners must support serving-size clarity and batch reports before launch. The United States CBD gummies outlook gives suppliers a useful view of how online education affects gummy sales.

Key Growth Drivers

• Online retail strength gives private label CBD brands more room to sell directly. USA Census Bureau reported in May 2026 that first-quarter 2026 seasonally adjusted retail e-commerce sales reached USD 326.7 billion.
• CBD gummy channel expansion now includes controlled app-based access. DoorDash launched hemp-derived THC and CBD product delivery in select USA states in January 2025 with electronic identification checks.
• Private label suppliers reduce launch cost for startup wellness brands. This is useful for brands testing gummies before building a larger product line.
• Contract gummy production supports faster product changes. Brands can adjust flavor or packaging without buying their own confectionery equipment.

Key Restraints

• Federal CBD rules limit disease-treatment claims on non-prescription gummies.
• Retailers can delay edible CBD listings if label files are incomplete.
• Compliance risk is higher for products using medical language. Food and Drug Administration issued a warning letter in August 2024 after reviewing CBD products marketed with disease-treatment claims.

What makes United States unique

The United States differs because private label CBD gummy suppliers and online brand builders are both well developed.

Key Companies

• CBD Nationwide
• Extract Labs
• cbdMD, Inc.
• CV Sciences, Inc.
• Charlotte’s Web Holdings, Inc.

Sales & Marketing Channels

• Brand websites
• Wholesale CBD programs
• Specialist wellness retail
• Contract manufacturing sales
• Subscription programs

Country Segment Breakdown Table

Segment	Sub-Segments
By Service Model	White Label Gummies, Custom Formulation, Contract Manufacturing, Co-Packing, Bulk Gummies
By CBD Spectrum	Broad-Spectrum CBD Gummies, Full-Spectrum CBD Gummies, CBD Isolate Gummies, Minor Cannabinoid Blends, THC-Free Gummies
By Dosage Strength	Low Dose, Mid Dose, High Dose, Microdose, Split Dose
By Sales Channel	Brand Websites, Specialist Retail, Pharmacy-Style Retail, Licensed Cannabis Retail, Marketplace Sellers
By Buyer Type	Startup Brands, Wellness Retailers, Cannabis Retailers, Practitioner Brands, Digital Wellness Brands
Key Sub-Regions Covered, States / Commercial Areas	California, Colorado, Oregon, Nevada, New York, Florida, Texas

Frequently Asked Questions

How fast is the United States private label CBD gummies market growing?

The United States is forecast to record 8.5% CAGR from 2026 to 2036. Online selling and supplier depth guide the outlook.

Who leads the United States private label CBD gummies market?

CBD Nationwide, Extract Labs, and cbdMD, Inc. are active companies in the USA CBD gummy supply space.

What is driving adoption of private label CBD gummies in the United States?

Brand website selling leads adoption. Outsourced gummy production and clear serving guidance support the same path.

Demand Outlook for Private Label CBD Gummies Market in Canada

Regulated edible manufacturing, 2026 to 2036

Country Market Snapshot Table

Parameter	Value
Market Size in 2025 (Value)	USD 74.6 million
Market Forecast in 2036 (Value)	USD 176.3 million
CAGR (2026-2036)	8.1%
Years Considered	2021-2036
Base Year	2025
Forecast Period	2026-2036
Units Considered	Value (USD million)
Leading Sub-Region	Ontario and British Columbia licensed retail corridor

Canada Private Label CBD Gummies Market Outlook

Canadian private label CBD gummies demand works through a more controlled edible cannabis system. Brands need licensed production support and strict packaging discipline.

Private label opportunities are stronger for suppliers that understand regulated edible limits. Retail access is more formal than open wellness channels. Suppliers with cannabis concentrate experience can understand why cannabinoid documentation matters across regulated channels.

Key Growth Drivers

• Legal cannabis use gives consumers more exposure to edible formats. Health Canada reported in March 2026 that 26.0% of people aged 16 and older used cannabis for non-medical purposes in the prior 12 months.
• Online retail helps brands test private label products at smaller scale. Statistics Canada reported retail e-commerce sales of CAD 4.2 billion in June 2025.
• Licensed edible producers can help new brands meet label and package requirements. This lowers entry risk for companies without cannabis production assets.
• Provincial retail systems give private label brands structured selling paths. This reduces channel confusion for new edible products.

Key Restraints

• Product access differs across provinces, which can slow national rollout.
• Packaging controls make edible gummies harder to scale quickly.
• Edible THC limits restrict high-strength product design. Health Canada’s July 2025 guide states each immediate container of edible cannabis cannot contain more than 10.0 mg THC.

What makes Canada unique

Canada differs because private label CBD gummies need licensed edible discipline and province-by-province route planning.

Key Companies

• MediPharm Labs Corp.
• Tilray Brands, Inc.
• Organigram Global Inc.
• Aurora Cannabis Inc.
• Indiva Limited

Sales & Marketing Channels

• Licensed cannabis retail
• Provincial online portals
• Medical cannabis channels
• Contract manufacturing sales
• Specialist wellness stores

Country Segment Breakdown Table

Segment	Sub-Segments
By Service Model	White Label Gummies, Custom Formulation, Contract Manufacturing, Co-Packing, Bulk Gummies
By CBD Spectrum	Broad-Spectrum CBD Gummies, Full-Spectrum CBD Gummies, CBD Isolate Gummies, Minor Cannabinoid Blends, THC-Free Gummies
By Dosage Strength	Low Dose, Mid Dose, High Dose, Microdose, Split Dose
By Sales Channel	Brand Websites, Specialist Retail, Pharmacy-Style Retail, Licensed Cannabis Retail, Marketplace Sellers
By Buyer Type	Startup Brands, Wellness Retailers, Cannabis Retailers, Practitioner Brands, Digital Wellness Brands
Key Sub-Regions Covered, Provinces / Commercial Areas	Ontario, British Columbia, Alberta, Quebec, Manitoba, Nova Scotia, Saskatchewan

Frequently Asked Questions

How fast is the Canada private label CBD gummies market growing?

Canada is forecast to record 8.1% CAGR from 2026 to 2036. Regulated edible access and retail controls guide the outlook.

Who leads the Canada private label CBD gummies market?

MediPharm Labs Corp., Tilray Brands, Inc., and Organigram Global Inc. are active cannabinoid companies in Canada.

What is driving adoption of private label CBD gummies in Canada?

Licensed edible manufacturing anchors adoption. Provincial retail systems and controlled packaging rules add support.

Demand Outlook for Private Label CBD Gummies Market in the United Kingdom

CBD product-list discipline, 2026 to 2036

Country Market Snapshot Table

Parameter	Value
Market Size in 2025 (Value)	USD 63.8 million
Market Forecast in 2036 (Value)	USD 145.8 million
CAGR (2026-2036)	7.8%
Years Considered	2021-2036
Base Year	2025
Forecast Period	2026-2036
Units Considered	Value (USD million)
Leading Sub-Region	England wellness retail corridor

United Kingdom Private Label CBD Gummies Market Outlook

UK private label CBD gummies demand depends on product-list status and clear documentation. Brand owners need suppliers that understand edible CBD rules before launch.

Private label suppliers can help brands keep label wording simple. This is important for retailers that screen CBD products before stocking them. The Europe CBD gummies outlook shows why product files and retailer review remain central across the region.

Key Growth Drivers

• Online retail gives CBD brands a clear selling route. Office for National Statistics reported in December 2025 that online sales accounted for 28.6% of retail sales in November 2025.
• Reformulation guidance gives listed CBD products a safer adjustment route. Food Standards Agency said in July 2025 that businesses could reformulate products on the public list to meet a provisional acceptable daily intake of 10.0 mg CBD.
• Specialist retailers help new brands explain dose and CBD spectrum type. This is useful for private label products entering high-street wellness shelves.
• White label gummies can reduce launch time for smaller UK brands. Suppliers with existing product files can support faster retail review.

Key Restraints

• Novel food review can slow new private label launches.
• Retailers may reject products without clear product-list status.
• Product eligibility rules narrow the launch path. Food Standards Agency states that CBD products must have been on sale before 13 February 2020 and linked to applications filed before 31 March 2021.

What makes United Kingdom unique

The United Kingdom differs because private label CBD gummies need clear product-list support before wider retail entry.

Key Companies

• British Cannabis
• Cannaray Limited
• Naturecan Ltd.
• Orange County CBD
• Reakiro CBD

Sales & Marketing Channels

• Specialist wellness retail
• Brand websites
• Pharmacy-style retail
• Marketplace sellers
• Contract manufacturing sales

Country Segment Breakdown Table

Segment	Sub-Segments
By Service Model	White Label Gummies, Custom Formulation, Contract Manufacturing, Co-Packing, Bulk Gummies
By CBD Spectrum	Broad-Spectrum CBD Gummies, Full-Spectrum CBD Gummies, CBD Isolate Gummies, Minor Cannabinoid Blends, THC-Free Gummies
By Dosage Strength	Low Dose, Mid Dose, High Dose, Microdose, Split Dose
By Sales Channel	Brand Websites, Specialist Retail, Pharmacy-Style Retail, Licensed Cannabis Retail, Marketplace Sellers
By Buyer Type	Startup Brands, Wellness Retailers, Cannabis Retailers, Practitioner Brands, Digital Wellness Brands
Key Sub-Regions Covered, Countries / Commercial Areas	England, Scotland, Wales, Northern Ireland, London Area, Midlands, South East England

Frequently Asked Questions

How fast is the United Kingdom private label CBD gummies market growing?

The United Kingdom is forecast to record 7.8% CAGR from 2026 to 2036. Product-list discipline and online retail guide the outlook.

Who leads the United Kingdom private label CBD gummies market?

British Cannabis, Cannaray Limited, and Naturecan Ltd. are active CBD companies in the United Kingdom.

What is driving adoption of private label CBD gummies in the United Kingdom?

Retailer review guides adoption. Product-list status and online CBD education add support.

Demand Outlook for Private Label CBD Gummies Market in Germany

Cannabinoid awareness and retail documentation, 2026 to 2036

Country Market Snapshot Table

Parameter	Value
Market Size in 2025 (Value)	USD 49.2 million
Market Forecast in 2036 (Value)	USD 108.8 million
CAGR (2026-2036)	7.5%
Years Considered	2021-2036
Base Year	2025
Forecast Period	2026-2036
Units Considered	Value (USD million)
Leading Sub-Region	North Rhine-Westphalia and Bavaria retail corridors

Germany Private Label CBD Gummies Market Outlook

German private label CBD gummies demand is guided by cannabinoid awareness and strict food retail review. Brands need German-language labels and complete batch documents.

Private label suppliers can support smaller brands that do not have their own compliance teams. Retail entry still needs careful product files.

Key Growth Drivers

• Cannabis policy change has increased cannabinoid discussion in Germany. The Federal Ministry of Health stated in August 2024 that cultivation associations may pass on up to 25.0 g per day and 50.0 g per month to adult members.
• Adult-use policy creates more public familiarity with cannabis products. Germany’s Cannabis Act came into force in key parts on 1 April 2024.
• Online stores help private label brands explain broad-spectrum gummies before purchase. This supports products that need more detail than standard sweets.
• German retailers prefer clear testing and warning language. Private label suppliers with ready documents can improve brand entry.

Key Restraints

• CBD edible status can slow retail review.
• German-language label and safety files raise launch cost for smaller brands.
• Young-adult restrictions limit broader cannabis messaging. The Federal Ministry of Health states that members under 21 may receive no more than 30.0 g per month with THC not over 10.0%.

What makes Germany unique

Germany differs because cannabinoid awareness is rising and retail documentation standards stay strict.

Key Companies

• Sanity Group GmbH
• Cannamedical Pharma GmbH
• Drapalin Pharmaceuticals GmbH
• Four 20 Pharma GmbH
• Nordic Oil GmbH

Sales & Marketing Channels

• Online wellness stores
• Specialist CBD retail
• Pharmacy-style advice channels
• Medical cannabis channels
• Contract manufacturing sales

Country Segment Breakdown Table

Segment	Sub-Segments
By Service Model	White Label Gummies, Custom Formulation, Contract Manufacturing, Co-Packing, Bulk Gummies
By CBD Spectrum	Broad-Spectrum CBD Gummies, Full-Spectrum CBD Gummies, CBD Isolate Gummies, Minor Cannabinoid Blends, THC-Free Gummies
By Dosage Strength	Low Dose, Mid Dose, High Dose, Microdose, Split Dose
By Sales Channel	Brand Websites, Specialist Retail, Pharmacy-Style Retail, Licensed Cannabis Retail, Marketplace Sellers
By Buyer Type	Startup Brands, Wellness Retailers, Cannabis Retailers, Practitioner Brands, Digital Wellness Brands
Key Sub-Regions Covered, States / Commercial Areas	North Rhine-Westphalia, Bavaria, Baden-Württemberg, Berlin, Hesse, Lower Saxony, Hamburg

Frequently Asked Questions

How fast is the Germany private label CBD gummies market growing?

Germany is forecast to record 7.5% CAGR from 2026 to 2036. Cannabinoid awareness and strict retailer review guide the outlook.

Who leads the Germany private label CBD gummies market?

Sanity Group GmbH, Cannamedical Pharma GmbH, and Nordic Oil GmbH are active companies in Germany’s cannabinoid space.

What is driving adoption of private label CBD gummies in Germany?

Online education supports buyer entry. Retailer documentation and broad-spectrum product interest add support.

Demand Outlook for Private Label CBD Gummies Market in Australia

Practitioner-linked CBD review, 2026 to 2036

Country Market Snapshot Table

Parameter	Value
Market Size in 2025 (Value)	USD 37.5 million
Market Forecast in 2036 (Value)	USD 80.8 million
CAGR (2026-2036)	7.3%
Years Considered	2021-2036
Base Year	2025
Forecast Period	2026-2036
Units Considered	Value (USD million)
Leading Sub-Region	New South Wales and Victoria practitioner corridors

Australia Private Label CBD Gummies Market Outlook

Australian private label CBD gummies demand is influenced by medical cannabis access and pharmacy review. Brand owners need careful formulation and dosage support.

The market has a more formal product path than open wellness retail. Private label suppliers need complete documentation before serving consumer-facing brands.

Key Growth Drivers

• Medical cannabis access has made cannabinoid products easier to discuss. Therapeutic Goods Administration reported in August 2025 that more than 1.0 million patients had accessed unapproved medicinal cannabis products.
• Low-dose CBD rules create a pathway for pharmacy-based products. Therapeutic Goods Administration allows approved low-dose CBD products up to 150.0 mg per day for adults through pharmacist supply.
• Practitioner-linked education helps buyers understand dose and timing. This supports private label brands with clearer product information.
• Pharmacy-style review gives compliant suppliers a stronger route. Private label partners must prepare labels and warnings before launch.

Key Restraints

• Non-prescription CBD edible routes are difficult without product approval.
• Small brands may struggle with evidence and documentation costs.
• Product access depends on strict approval requirements. Therapeutic Goods Administration states that over-the-counter supply applies only to products approved by TGA and included on the Australian Register of Therapeutic Goods.

What makes Australia unique

Australia differs because CBD gummies need stronger health-product discipline than general wellness gummies.

Key Companies

• Little Green Pharma Ltd.
• Cann Group Limited
• Althea Group Holdings Limited
• Montu Group Pty Ltd.
• ECS Botanics Holdings Ltd.

Sales & Marketing Channels

• Practitioner channels
• Pharmacy guidance
• Medical cannabis platforms
• Brand websites
• Specialist wellness stores

Country Segment Breakdown Table

Segment	Sub-Segments
By Service Model	White Label Gummies, Custom Formulation, Contract Manufacturing, Co-Packing, Bulk Gummies
By CBD Spectrum	Broad-Spectrum CBD Gummies, Full-Spectrum CBD Gummies, CBD Isolate Gummies, Minor Cannabinoid Blends, THC-Free Gummies
By Dosage Strength	Low Dose, Mid Dose, High Dose, Microdose, Split Dose
By Sales Channel	Brand Websites, Specialist Retail, Pharmacy-Style Retail, Licensed Cannabis Retail, Marketplace Sellers
By Buyer Type	Startup Brands, Wellness Retailers, Cannabis Retailers, Practitioner Brands, Digital Wellness Brands
Key Sub-Regions Covered, States / Commercial Areas	New South Wales, Victoria, Queensland, Western Australia, South Australia, Tasmania, Australian Capital Territory

Frequently Asked Questions

How fast is the Australia private label CBD gummies market growing?

Australia is forecast to record 7.3% CAGR from 2026 to 2036. Medical cannabis familiarity and pharmacy review guide the outlook.

Who leads the Australia private label CBD gummies market?

Little Green Pharma Ltd., Cann Group Limited, and Althea Group Holdings Limited are active companies in Australia’s cannabinoid market.

What is driving adoption of private label CBD gummies in Australia?

Practitioner guidance shapes adoption. Pharmacy review and low-dose CBD product interest support the route.

Demand Outlook for Private Label CBD Gummies Market in the Netherlands

Controlled cannabis supply and compact online retail, 2026 to 2036

Country Market Snapshot Table

Parameter	Value
Market Size in 2025 (Value)	USD 19.4 million
Market Forecast in 2036 (Value)	USD 40.0 million
CAGR (2026-2036)	6.9%
Years Considered	2021-2036
Base Year	2025
Forecast Period	2026-2036
Units Considered	Value (USD million)
Leading Sub-Region	Randstad wellness retail corridor

Netherlands Private Label CBD Gummies Market Outlook

Dutch private label CBD gummies demand is smaller than in the United States or Canada. Online education and specialist shops carry much of the buyer explanation work.

Private label brands need clear lab reports and simple labels. Compact geography makes targeted online selling easier than broad store rollout.

Key Growth Drivers

• Regulated supply trials are improving product-quality discussion. The Government of the Netherlands stated in December 2024 that participating coffee shops would sell only regulated cannabis from 7 April 2025.
• Product-quality oversight is central to the cannabis supply experiment. The Government of the Netherlands stated that 70 of 75 participating coffee shops had sold regulated weed and hash after nearly one year of regulated supply.
• Online CBD retail helps small brands reach buyers without large shelf expansion. This favors private label brands with limited early budgets.
• Specialist shops can explain dose and CBD spectrum type. This helps new private label products avoid confusing shelf copy.

Key Restraints

• Market size is small, which can limit broad retail expansion.
• Product trust depends heavily on lab reports and simple Dutch-language labels.
• Cannabis tolerance rules still limit open product freedom. Government guidance says public possession tolerated under strict conditions is no more than 5 g of cannabis and 5 cannabis plants.

What makes Netherlands unique

The Netherlands differs because controlled supply trials make product quality a stronger part of consumer discussion.

Key Companies

• Jacob Hooy & Co. B.V.
• Dutch Natural Healing B.V.
• Endoca B.V.
• Cibdol AG
• Sensi Seeds B.V.

Sales & Marketing Channels

• Brand websites
• Specialist CBD shops
• Health stores
• Pharmacy-style retail
• Contract manufacturing sales

Country Segment Breakdown Table

Segment	Sub-Segments
By Service Model	White Label Gummies, Custom Formulation, Contract Manufacturing, Co-Packing, Bulk Gummies
By CBD Spectrum	Broad-Spectrum CBD Gummies, Full-Spectrum CBD Gummies, CBD Isolate Gummies, Minor Cannabinoid Blends, THC-Free Gummies
By Dosage Strength	Low Dose, Mid Dose, High Dose, Microdose, Split Dose
By Sales Channel	Brand Websites, Specialist Retail, Pharmacy-Style Retail, Licensed Cannabis Retail, Marketplace Sellers
By Buyer Type	Startup Brands, Wellness Retailers, Cannabis Retailers, Practitioner Brands, Digital Wellness Brands
Key Sub-Regions Covered, Provinces / Commercial Areas	North Holland, South Holland, Utrecht, North Brabant, Gelderland, Limburg, Groningen

Frequently Asked Questions

How fast is the Netherlands private label CBD gummies market growing?

The Netherlands is forecast to record 6.9% CAGR from 2026 to 2036. Controlled supply discussion and online CBD retail guide the outlook.

Who leads the Netherlands private label CBD gummies market?

Jacob Hooy & Co. B.V., Dutch Natural Healing B.V., and Endoca B.V. are active CBD-focused companies serving Dutch buyers.

What is driving adoption of private label CBD gummies in the Netherlands?

Online education carries early adoption. Specialist shops and product-quality discussion add support.

Demand Outlook for Private Label CBD Gummies Market in France

Safety-led CBD edible review, 2026 to 2036

Country Market Snapshot Table

Parameter	Value
Market Size in 2025 (Value)	USD 16.8 million
Market Forecast in 2036 (Value)	USD 32.7 million
CAGR (2026-2036)	6.4%
Years Considered	2021-2036
Base Year	2025
Forecast Period	2026-2036
Units Considered	Value (USD million)
Leading Sub-Region	Île-de-France and southern wellness corridors

France Private Label CBD Gummies Market Outlook

French private label CBD gummies demand is cautious because edible CBD products face safety review. Brands need careful sourcing and plain product wording.

Specialist CBD stores can help explain serving size and product type. Private label suppliers need clean files before selling to French brand owners.

Key Growth Drivers

• Older adult wellness demand gives CBD brands a defined buyer group. Institut national de la statistique et des études économiques reported in January 2026 that 22% of France’s population was aged sixty- five or over.
• Longer life expectancy supports interest in daily wellness routines. Institut national de la statistique et des études économiques reported in January 2026 that life expectancy reached eighty- five years and nine months for women and eighty years and three months for men in 2025.
• Specialist CBD stores give private label brands a route for consumer education. This helps products that need explanation before purchase.
• Low-dose formats fit cautious buyers who want a simple entry product. Private label suppliers can support this through controlled serving design.

Key Restraints

• Safety concerns can make retailers more careful with CBD sweets and capsules.
• Product sourcing needs to be clear before wider private label entry.
• Poisoning reports can limit aggressive edible claims. ANSES reported in June 2025 that poisoning cases linked to CBD products had increased since the beginning of 2024.

What makes France unique

France is rising as safety review can slow CBD gummy launches even when specialist retail demand exists.

Key Companies

• La Ferme du CBD SAS
• Greeneo SAS
• Ho Karan SAS
• Marie Jeanne SAS
• Stormrock SAS

Sales & Marketing Channels

• Specialist CBD stores
• Brand websites
• Wellness retailers
• Pharmacy-style advice points
• Contract manufacturing sales

Country Segment Breakdown Table

Segment	Sub-Segments
By Service Model	White Label Gummies, Custom Formulation, Contract Manufacturing, Co-Packing, Bulk Gummies
By CBD Spectrum	Broad-Spectrum CBD Gummies, Full-Spectrum CBD Gummies, CBD Isolate Gummies, Minor Cannabinoid Blends, THC-Free Gummies
By Dosage Strength	Low Dose, Mid Dose, High Dose, Microdose, Split Dose
By Sales Channel	Brand Websites, Specialist Retail, Pharmacy-Style Retail, Licensed Cannabis Retail, Marketplace Sellers
By Buyer Type	Startup Brands, Wellness Retailers, Cannabis Retailers, Practitioner Brands, Digital Wellness Brands
Key Sub-Regions Covered, Regions / Commercial Areas	Île-de-France, Auvergne-Rhône-Alpes, Provence-Alpes-Côte d’Azur, Nouvelle-Aquitaine, Occitanie, Brittany, Grand Est

Frequently Asked Questions

How fast is the France private label CBD gummies market growing?

France is forecast to record 6.4% CAGR from 2026 to 2036. Safety review keeps the outlook more cautious than North America.

Who leads the France private label CBD gummies market?

La Ferme du CBD SAS, Greeneo SAS, and Ho Karan SAS are active CBD-focused companies in France.

What is driving adoption of private label CBD gummies in France?

Specialist retail leads adoption. Online selling and low-dose product interest add support

Private Label CBD Gummies Market - Report Scope

Parameter	Details
Market size by 2036	USD 1,382.2 million
Growth rate	7.9% CAGR from 2026 to 2036
Forecast period	2026 to 2036
Base year value in 2025	USD 598.9 million
By service model	White label gummies, custom formulation, contract manufacturing, co-packing, bulk gummies
By CBD spectrum	Broad-spectrum CBD gummies, full-spectrum CBD gummies, CBD isolate gummies, minor cannabinoid blends, THC-free gummies
By dosage strength	Low dose, mid dose, high dose, microdose, split dose
By sales channel	Brand websites, specialist retail, pharmacy-style retail, licensed cannabis retail, marketplace sellers
By buyer type	Startup brands, wellness retailers, cannabis retailers, practitioner brands, digital wellness brands
Regions covered	North America, Europe, Oceania
Countries covered	United States, Canada, United Kingdom, Germany, Australia, Netherlands, France
Key companies profiled	CBD Nationwide, Extract Labs, cbdMD, Inc., Charlotte’s Web Holdings, Inc., CV Sciences, Inc., Medterra CBD LLC, British Cannabis, Cannaray Limited, MediPharm Labs Corp., Little Green Pharma Ltd.
Approach	Bottom-up product-boundary approach using eligible private label gummy revenue, supplier coverage, retail pricing, product positioning, and country-level adoption

Source: Future Market Insights, 2026.

Private Label CBD Gummies Market Breakdown by Service Model, CBD Spectrum, Dosage Strength, Sales Channel, Buyer Type, and Region

By Service Model

• White Label Gummies
• Custom Formulation
• Contract Manufacturing
• Co-Packing
• Bulk Gummies

By CBD Spectrum

• Broad-Spectrum CBD Gummies
• Full-Spectrum CBD Gummies
• CBD Isolate Gummies
• Minor Cannabinoid Blends
• THC-Free Gummies

By Dosage Strength

• Low Dose
• Mid Dose
• High Dose
• Microdose
• Split Dose

By Sales Channel

• Brand Websites
• Specialist Retail
• Pharmacy-Style Retail
• Licensed Cannabis Retail
• Marketplace Sellers

By Buyer Type

• Startup Brands
• Wellness Retailers
• Cannabis Retailers
• Practitioner Brands
• Digital Wellness Brands

By Region

• North America
• Europe
• Oceania

Questions Answered by the Report

• How large is the private label CBD gummies market in 2026 and by 2036?
• Which service model and CBD spectrum carry the strongest 2026 share?
• How do country rates differ across the United States, Canada, the United Kingdom, Germany, Australia, the Netherlands, and France?
• Which regulatory signals control private label CBD gummy launches?
• Which companies are active in private label CBD gummy production and related gummy supply?
• How should suppliers define eligible revenue without using parent-market shortcuts?
• Which sales channels are most useful for private label CBD gummy education?
• Which products must be excluded from the market boundary?

Research Sources and Bibliography

• CBD Nationwide. (2025, September 26). How to scale your private label cannabis & hemp operations. CBD Nationwide.
• cbdMD, Inc. (2024, May 16). cbdMD launches Max Chill Dragon Fruit D9 Gummies: Your go-to relaxation blend for the summer. cbdMD, Inc.
• Charlotte’s Web Holdings, Inc. (2024, October 7). Tilray Brands launches Charlotte’s Web CBD Gummies in Canada. Charlotte’s Web Holdings, Inc.
• Charlotte’s Web Holdings, Inc. (2025, August 13). Charlotte’s Web reports year-over-year growth for Q2 2025. Charlotte’s Web Holdings, Inc.
• CV Sciences, Inc. (2025, February 5). CV Sciences unveils new Aura Collection THC Fizz Tablets. CV Sciences, Inc.
• DoorDash. (2025, January 9). DoorDash expands offerings to include hemp-derived products in select states. DoorDash.
• Extract Labs. (2025). Unveiling excellence: Gummy manufacturing by Extract Labs. Extract Labs.
• Food and Drug Administration. (2024, August 30). Root Bioscience Brands, LLC dba Naternal - 673646 - 08/30/2024. USA Food and Drug Administration.
• Food Standards Agency. (2025, July 1). Food Standards Agency updates guidance allowing CBD businesses to reformulate products on the public list for safety reasons. Food Standards Agency.
• Food Standards Agency. (2026, April 13). Register of CBD products linked to novel food applications. Food Standards Agency.
• European Food Safety Authority. (2026, February 9). Provisional safe level for cannabidiol as a novel food. European Food Safety Authority.
• Health Canada. (2025, July 15). Packaging and labelling guide for cannabis products. Government of Canada.
• Health Canada. (2026, March 6). Canadian Cannabis Survey 2024: Summary. Government of Canada.
• Medterra CBD LLC. (2025, September 8). What dosage of CBD gummies for sleep? Medterra CBD LLC.
• Office for National Statistics. (2025, December 19). Retail sales, Great Britain: November 2025. Office for National Statistics.
• Statistics Canada. (2025, August 22). Retail trade, June 2025. Statistics Canada.
• The Federal Ministry of Health. (2024, August 22). Frequently asked questions on the Cannabis Act. Federal Ministry of Health Germany.
• Therapeutic Goods Administration. (2025, August). Reviewing the safety and regulatory oversight of unapproved medicinal cannabis products: Consultation paper. Australian Government Department of Health and Aged Care.
• USA Census Bureau. (2026, May 18). Quarterly retail e-commerce sales: 1st quarter 2026. USA Census Bureau.
• Government of the Netherlands. (2024, December 10). Experimental phase of the Closed Coffee Shop Chain Experiment to begin in April. Government of the Netherlands.
• Government of the Netherlands. (2025, April 30). Rules for the experiment with a controlled supply of cannabis to coffee shops. Government of the Netherlands.
• Agence nationale de sécurité sanitaire de l’alimentation, de l’environnement et du travail. (2025, June 19). Increase in cases of poisoning caused by CBD products containing other substances. ANSES.
• Institut national de la statistique et des études économiques. (2026, January 13). Demographic report 2025. INSEE.

This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations.